ING Groep NV Lowers Stock Holdings in CVS Health Corporation $CVS

ING Groep NV cut its holdings in CVS Health Corporation (NYSE:CVS) by 14.5% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 143,177 shares of the pharmacy operator’s stock after selling 24,288 shares during the quarter. ING Groep NV’s holdings in CVS Health were worth $10,794,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. SOA Wealth Advisors LLC. lifted its holdings in CVS Health by 36.9% during the third quarter. SOA Wealth Advisors LLC. now owns 486 shares of the pharmacy operator’s stock valued at $37,000 after purchasing an additional 131 shares in the last quarter. Symmetry Partners LLC lifted its stake in CVS Health by 2.5% in the 3rd quarter. Symmetry Partners LLC now owns 5,826 shares of the pharmacy operator’s stock valued at $439,000 after buying an additional 141 shares in the last quarter. Harbor Capital Advisors Inc. boosted its holdings in CVS Health by 72.1% in the 3rd quarter. Harbor Capital Advisors Inc. now owns 339 shares of the pharmacy operator’s stock worth $26,000 after buying an additional 142 shares during the last quarter. HF Advisory Group LLC increased its stake in CVS Health by 2.9% during the 3rd quarter. HF Advisory Group LLC now owns 5,219 shares of the pharmacy operator’s stock worth $393,000 after buying an additional 145 shares in the last quarter. Finally, United Asset Strategies Inc. raised its holdings in shares of CVS Health by 1.8% during the third quarter. United Asset Strategies Inc. now owns 8,852 shares of the pharmacy operator’s stock valued at $667,000 after acquiring an additional 154 shares during the last quarter. Hedge funds and other institutional investors own 80.66% of the company’s stock.

CVS Health Stock Performance

NYSE CVS opened at $76.88 on Thursday. The stock has a market cap of $97.59 billion, a PE ratio of 55.71, a P/E/G ratio of 0.70 and a beta of 0.50. CVS Health Corporation has a twelve month low of $58.35 and a twelve month high of $85.15. The stock has a fifty day simple moving average of $78.55 and a 200-day simple moving average of $75.98. The company has a current ratio of 0.84, a quick ratio of 0.63 and a debt-to-equity ratio of 0.80.

CVS Health (NYSE:CVS) last posted its earnings results on Tuesday, February 10th. The pharmacy operator reported $1.09 EPS for the quarter, beating analysts’ consensus estimates of $1.00 by $0.09. The company had revenue of $105.69 billion for the quarter, compared to analysts’ expectations of $103.67 billion. CVS Health had a net margin of 0.44% and a return on equity of 11.31%. CVS Health’s revenue for the quarter was up 8.2% compared to the same quarter last year. During the same quarter in the prior year, the company posted $1.19 earnings per share. CVS Health has set its FY 2026 guidance at 5.940-6.140 EPS. Equities analysts anticipate that CVS Health Corporation will post 5.89 earnings per share for the current year.

CVS Health Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Monday, February 2nd. Shareholders of record on Thursday, January 22nd were given a $0.665 dividend. The ex-dividend date of this dividend was Thursday, January 22nd. This represents a $2.66 dividend on an annualized basis and a yield of 3.5%. CVS Health’s payout ratio is presently 700.00%.

Wall Street Analyst Weigh In

Several analysts recently commented on the company. Raymond James Financial boosted their price target on CVS Health from $75.00 to $90.00 in a research report on Friday, October 31st. Wolfe Research upped their target price on shares of CVS Health from $85.00 to $100.00 and gave the stock an “outperform” rating in a report on Monday, December 8th. Evercore increased their target price on shares of CVS Health from $85.00 to $95.00 and gave the company an “outperform” rating in a research report on Thursday, October 30th. Royal Bank Of Canada restated an “outperform” rating on shares of CVS Health in a research report on Thursday, December 4th. Finally, Morgan Stanley increased their price objective on shares of CVS Health from $89.00 to $93.00 and gave the company an “overweight” rating in a report on Wednesday, December 10th. Nineteen analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the stock. Based on data from MarketBeat.com, CVS Health presently has a consensus rating of “Moderate Buy” and a consensus price target of $94.82.

Key CVS Health News

Here are the key news stories impacting CVS Health this week:

• Positive Sentiment: Q4 beat and record revenue — CVS reported Q4 revenue of $105.7B (up 8.2%) and adjusted EPS that topped estimates, driven by Pharmacy and PBM strength; management cites progress on its turnaround. PR News Release
• Positive Sentiment: Analysts see multiple growth levers for 2026 — Sell‑side commentators highlight continued PBM, retail pharmacy margin recovery, and Aetna enrollment/efficiencies as upside drivers. Analysts See Multiple Growth Levers For CVS Health In 2026
• Positive Sentiment: Operational wins: cost‑based pharmacy transition & improved prior‑auth performance at Aetna — items that support margin recovery and execution credibility. PR News Release
• Neutral Sentiment: Sector context — Oscar Health and other insurers posted diverging 2025 results, keeping investor focus on insurer exposure and reimbursement trends rather than CVS‑specific fundamentals. CVS, Oscar Health report diverging 2025 results
• Neutral Sentiment: Mixed analyst commentary — some outlets and commentators (e.g., Jim Cramer) call CVS an attractive turnaround play, which supports sentiment but contrasts with caution around policy and guidance. Jim Cramer on CVS
• Negative Sentiment: Guidance shortfall vs. Street — management issued FY‑2026 EPS guidance (~$5.94–$6.14) below consensus estimates, prompting concern that near‑term earnings targets may be conservative versus sell‑side models. Zacks: Beats but Shares Slide
• Negative Sentiment: Medicare/MA rate concerns — investor worry about proposed Medicare rate changes and a “disappointing” 2027 Medicare Advantage rate notice from management weighed on sentiment and triggered earlier selling. Barron’s: Medicare Worries
• Negative Sentiment: Cash‑flow/guidance nuances — some reports flag lowered cash‑flow guidance or in‑line items that temper the upbeat revenue beat, which can pressure valuation near term. Investing.com: Cash Flow Guidance Lowered

CVS Health Profile

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over‑the‑counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in‑store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk‑in medical clinics and HealthHUB locations that offer expanded clinical services.